View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 4, 2011

ALKS 9070 Found Effective for Schizophrenia

Alkermes has reported the positive top-line results from a Phase Ib study of ALKS 9070, a drug used to treat schizophrenia. The 20-week double-blind, randomised, multicentre and placebo-controlled study enrolled 32 patients and demonstrated the safety, tolerability and pharmacokinetics

By cms admin

Alkermes has reported the positive top-line results from a Phase Ib study of ALKS 9070, a drug used to treat schizophrenia.

The 20-week double-blind, randomised, multicentre and placebo-controlled study enrolled 32 patients and demonstrated the safety, tolerability and pharmacokinetics of a single administration of three ascending doses of the drug.

Based on the results, Alkermes plans to advance ALKS 9070 into pivotal development by the end of 2011.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology